tirzepatide fda approval for weight loss Day 4: Zepbound (Tirzepatide – indication) Approved: November 2023 weight management Weight Loss: Up to 22.5% in clinical trials Similar to Mounjaro, but marketed specifically for weight management Eli Lilly's Tirzepatide Weight-Loss Drug

[46] on semaglutide, we found no increased risk of papillary thyroid carcinoma, the most common type of thyroid cancer, associated with tirzepatide [16,36]

Why Patients Choose Tirzepatide Over Semaglutide Patients who plateau on semaglutide sometimes experience renewed weight loss momentum after switching to tirzepatide, a phenomenon partly explained by the additional GIP receptor stimulation

Medications Compared Both DirectMeds and MedVi offer the two most commonly prescribed compounded GLP-1 medications: semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound)

However, this is off-label, and the clinical trials were all conducted with once-weekly dosing

Pricing for tirzepatide is a little higher, and tirzepatide is available as an injection or dissolving tablet